Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



5 of Last Week's Biggest Winners

What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.


March 1

Weekly Gain

MediciNova (NASDAQ: MNOV  )



MGIC Investment (NYSE: MTG  )









Celldex Therapeutics (NASDAQ: CLDX  )



Source: Barron's.

MediciNova was an obscure and thinly traded biotech until it received fast-track designation from the FDA for its potentially promising treatment of methamphetamine dependence on Monday afternoon. Fast-track status grants an expedited review of drugs that aim to fill an unmet medical niche or treat serious diseases. More than 6 million shares of MediciNova traded hands last week, and it's safe to say that MediciNova will no longer be an obscure and thinly traded biotech.

MGIC soared despite posting its 10th consecutive quarterly loss on Thursday. The shares rallied on the market's confidence that home prices in general will continue to firm, making MGIC's dicey portfolio less risky.

MAKO Surgical also bounced back after posting uninspiring financial results. They key here is that the company behind the RIO surgical robotics system for orthopedic procedures had already braced investors for the soft showing back in January. The market was won over by its cautious outlook for the year ahead, calling for the sale of 45 to 48 new RIO systems and roughly 13,500 to 14,500 procedures for all of 2013.

Ebix bounced back after getting pounded a week earlier on a bearish report. The insurance industry software specialist rose after hosting a conference call to refute the negative claims in the report. Ebix was apparently convincing enough to gain back a good chunk of the prior week's hit.

Celldex Therapeutics has now come through with three straight weeks featuring gains of 8% or better. Momentum continues to build after revealing positive test results for its treatment for hematopoietic stem cell transplantation last month.

Keep the good vibes coming
To learn more about a few ETFs that have great promise for delivering profits to shareholders in a recovering global economy, check out The Motley Fool's special free report "3 ETFs Set to Soar During the Recovery." Just click here to access it now.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2289582, ~/Articles/ArticleHandler.aspx, 9/28/2016 3:08:37 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 5 hours ago Sponsored by:
DOW 18,228.30 133.47 0.74%
S&P 500 2,159.93 13.83 0.64%
NASD 5,305.71 48.22 0.92%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 4:00 PM
CLDX $4.23 Up +0.43 +11.32%
Celldex Therapeuti… CAPS Rating: ****
EBIX $56.44 Up +0.73 +1.31%
Ebix CAPS Rating: ***
MAKO.DL $0.00 Down +0.00 +0.00%
MAKO Surgical CAPS Rating: ****
MNOV $7.56 Up +0.09 +1.20%
MediciNova CAPS Rating: *
MTG $7.98 Up +0.06 +0.76%
MGIC Investment CAPS Rating: ***